SOPHiA GENETICS Q3 2026 Earnings Call - SOPHIA GENETICS SA

Financial Performance:

• Q3 2026 total revenue reached $24.3 million, representing 25% year-over-year growth (26% on a constant currency basis).
• Adjusted EBITDA loss narrowed to $6.1 million, a 31% improvement year-over-year from $8.8 million; management converted nearly 60% of incremental revenue to the bottom line.
• Gross margin stood at 65.7% (adjusted gross margin 72.8%), showing sequential improvement despite higher initial implementation costs for new accounts.
• Operating loss was $17.8 million, down from $17.9 million in the prior year, excluding a stock-based compensation charge increase.
• Cash position totaled $94 million at quarter-end, sufficient to fund operations and long-term goals.
• Net dollar retention improved to 118% from 108% in the prior year, while annualized revenue churn remained under 1%.

Guidance and Future Outlook:

• Full-year 2026 revenue guidance updated to the upper end of the range ($94–$96 million), driven by strong growth partially offset by foreign exchange headwinds.
• Full-year 2026 adjusted EBITDA loss guidance reaffirmed at $29–$32 million (compared to $41.5 million loss in 2025).
• Management expects to cross over to positive adjusted EBITDA in the second half of 2027.
• 2027 revenue growth visibility is strong, with 95% of expected growth already signed or booked as of Q3.
• Foreign exchange fluctuations in September and October are expected to create a headwind for Q4 revenue, though constant currency growth remains robust.

Business Segments and Product Lines:

• U.S. market revenue grew 41%, driven by new accounts including North York, iGenomics, a major West Coast health system, PathGroup, and the University of Arkansas.
• Liquid biopsy volume surged >100% year-over-year (4,200 analyses) and 41% sequentially, with 85+ institutions signed, including University Hospital Augsburg and Agilis Diagnostics.
• Solid tumor testing grew 30%, led by the MSK ImpactFlex CGP test; new customers include AOU Pisana and Gentidos.
• Hematology (HEMO) and rare disorder volumes grew 28% and 29% respectively.
• Biopharma collaborations accelerated, including a new multimodal AI predictor deal with a top 10 pharma company for bladder cancer and companion diagnostic programs with AstraZeneca.
• Platform analysis volume hit a record 118,000 (19% YoY), spanning 75 countries and 551 connected institutions.

Market and Competitive Landscape:

• North America growth drove 45% regional revenue increase; Asia-Pacific grew 33%, and EMEA saw >200% growth in Norway and >100% in the UK.
• U.S. market dynamics are favorable with rising reimbursement rates, improving denial rates, and dropping sequencing costs encouraging in-house testing.
• Sophia is gaining traction in liquid biopsy outside the U.S., leveraging a new medical affairs function to drive evidence and adoption in Europe, Asia, and Latin America.
• Competition in solid tumors is intensifying, but Sophia leverages superior accuracy (e.g., MTAP detection) and lower costs compared to legacy platforms.
• The company maintains a distinct competitive moat through its "collective intelligence" AI engine trained on real-world data from a global network.

Risks and Challenges:

• Ongoing legal proceedings with Garden Biosciences: The Unified Patent Court in Paris rejected Garden's appeal and ordered them to pay legal fees; UK infringement claims remain pending but partially discontinued.
• Foreign exchange volatility impacting reported revenue figures in Q4.
• Implementation and ramp-up timelines for new customers and products may vary, though backlog remains high.
• Need to continue educating clinicians and payers outside the U.S. regarding liquid biopsy use cases and reimbursement.
• Balancing necessary investments in AI and clinical intelligence with the commitment to achieve profitability in H2 2027.

Management Commentary and Tone:

• Tone is highly confident and optimistic, emphasizing "strong business momentum" and successful execution.
• Management highlights "operating leverage" and a "tech-first, AI-native" approach as key drivers for cost discipline and scalability.
• Ross Mann (CEO) expressed pride in the team's ability to grow revenue without significant headcount increases, citing AI adoption for internal efficiency.
• George Cardosa (CFO) emphasized the durability of the business model with world-class retention metrics and a healthy pipeline.
• Management reiterated commitment to profitable growth, noting that 60% of incremental revenue is being converted to EBITDA.

Analyst Questions and Answers:

• Growth Sustainability: Management expects growth rates in solid tumor, hematology, and rare disorders to sustain or accelerate into 2027 due to new product introductions (e.g., MSK ImpactFlex, comprehensive heme panels).
• Biopharma Funnel: Biopharma is described as a major growth accelerator with a healthy pipeline; recent CDX wins signal successful product-market fit and risk mitigation for partners.
• Investment Strategy: Selective headcount additions in U.S. sales/marketing and medical affairs (specifically for liquid biopsy education) are planned for 2027 to support market expansion, but overall OpEx will remain controlled via AI efficiency.
• Backlog and Visibility: Despite high conversion, backlog remains high due to strong bookings; 95% of 2027 growth is already secured.
• PathGroup Deal: A major expansion with PathGroup for solid tumor and hematology is noted as a "marquee win" with significant ramp potential, though specific dollar values were not disclosed.
• Margin Trajectory: Gross margins are expected to improve sequentially as scale increases and the mix shifts toward higher-margin products like liquid biopsy.

Other Key Points:

• Sophia Genetics is positioning itself as a global "clinical intelligence" leader, not just a diagnostic company, by integrating genomic, radiomic, and clinical data.
• The company signed 30 new logos in Q3, including major institutions in Thailand, Brazil, and Australia.
• The "MSK Access" liquid biopsy platform is a key differentiator, allowing institutions to deploy testing in-house using Sophia's AI for accuracy.
• Management will participate in several upcoming investor conferences including UBS, Jefferies, and Citigroup.
• The company successfully transitioned from a "send-out" model to an in-house testing model for many U.S. customers, retaining data control and improving economics.